Clinical Data Revolution rises 40% as pancreatic cancer drug doubles survival BioSpaceIn a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) BioSpace In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. Clinical DataOncologyRead full story Post navigation Previous: IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacyNext: 220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026